Dialysis-Consumables Supply Recovery Leader

The mandate

Clinics have cancelled haemodialysis sessions although central dashboards show weeks of consumables. The apparent cover combines dialyser surface areas and membranes, incompatible bloodline sets, acid concentrates for different proportioning systems, missing bicarbonate and needles, held lots and stock unreachable before the next roster. Clinical teams compensate locally, making the national picture less reliable. The provider needs one temporary executive to govern complete treatment-ready sets by clinic and machine platform while protecting clinical prescription authority.

The leader starts in Cairo within seven days for seven months. In the first ten working days, all central, depot and clinic inventory will be classified by exact device compatibility, quality state, expiry, custody and reachable session. By day 30, the 82 clinics must plan complete consumable sets against rostered capacity and safe transfer times. Three import cycles, a peak-demand period and one port-delay exercise precede a four-week permanent-team handover.

Exit is earned when scheduled sessions have traceable complete-set cover; incompatible or held stock is excluded; cross-clinic transfers show donor consequence; import recovery reflects release and inland time; and no clinic improves its metric by cancelling demand early. The successor receives platform and clinic baselines, supplier constraints, allocation decisions, import cases, expiry exposures, emergency routes, quality holds and six weeks of forward coverage, then runs two national reviews independently.

The interim may reserve and transfer released company-owned consumables, prioritise depot dispatch, place call-offs within existing agreements, secure approved freight and approve recovery expenditure up to EGP 480 million. Clinicians own prescription, patient scheduling and suitability; Quality owns lot disposition and complaints; biomedical engineering controls machine configuration; pharmacists and regulators retain licensed decisions; Procurement awards structural contracts; site leaders govern care delivery.

Clinical protocol change, patient triage, machine substitution approval, product equivalence, Quality release, regulatory action, permanent network design and reimbursement sit outside scope. The leader cannot make a nominal session feasible by mixing unapproved components or overriding a clinician. Each protected session must show the prescribed or authorised dialyser family, compatible bloodline and concentrate, required ancillaries, released status, clinic arrival and contingency.

Why this seat is open

The former supply director resigned after central inventory and clinic cancellation data diverged during two import delays. A permanent search requires clinical-supply and multi-site operating depth that is scarce locally. The temporary leader must rebuild trust at individual-session level immediately, giving clinicians credible supply choices without turning logistics into a treatment decision-maker.

What you will own

• Reconcile stock by dialyser membrane and size, bloodline, needle, concentrate, bicarbonate, disinfectant, platform, lot and clinic.
• Convert clinic rosters into complete treatment-set demand with quality state, expiry and reachable-time constraints visible.
• Allocate released sets across clinics using clinical policy, session consequence, transfer time, alternate platform and donor-clinic exposure.
• Rebuild import recovery from supplier production through documentation, port, release, depot and final clinic rather than vessel arrival.
• Control emergency transfers with identity, custody, temperature where applicable, donor consequence and receipt confirmation recorded.
• Exercise a port delay and prove clinic, clinical, Quality, supplier, regulator and patient-communication escalation paths.
• Induct the permanent leader through three import cycles, live allocations and two independently chaired national reviews.

Candidate qualifications

• Held executive dialysis, renal-care, hospital consumables or comparable treatment-critical supply authority across many clinical sites.
• Has recovered haemodialysis sessions when incompatible products and incomplete sets distorted apparent inventory cover.
• Understands dialysers, bloodlines, needles, concentrates, machine platforms, clinic rosters, release status and treatment-set logic.
• Can allocate scarce approved supply while preserving clinician, Quality, biomedical, pharmacy and regulator decision rights.
• Has controlled cross-clinic transfers and import disruptions without hiding shortage through premature session cancellation.
• Completed a patient-critical recovery with durable clinic data, permanent leadership and tested emergency routines.

Non-negotiables

• Can start onsite in Cairo within seven days and sustain approximately fifty-five percent clinic, depot and supplier travel.
• Brings direct dialysis or treatment-critical consumables depth; general hospital procurement or clinic integration is insufficient.
• Will disclose device, pharmaceutical, distributor, freight, clinic and healthcare-investor relationships before appointment.
• Accepts no prescription, patient-priority, product-equivalence, Quality-release, biomedical, regulatory or care-delivery authority.

1. 49 words maximum. Describe dialysis inventory you excluded after machine or treatment-set compatibility failed.
2. 49 words maximum. Which measure prevents a clinic improving availability by cancelling sessions before shortage is recorded?
3. 49 words maximum. What device, distributor, clinic or freight relationship could compromise your independence?

---